{
  "id": "61f7d535882a024a10000034",
  "type": "list",
  "question": "What are the targets of avapritinib?",
  "ideal_answer": "Avapritinib is a novel inhibitor of KIT/PDGFRA. It is approved in the U.S. for the treatment of adults with PDGFRA exon 18-mutant unresectable or metastatic gastrointestinal stromal tumors.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30274985",
    "http://www.ncbi.nlm.nih.gov/pubmed/32615108",
    "http://www.ncbi.nlm.nih.gov/pubmed/31117741",
    "http://www.ncbi.nlm.nih.gov/pubmed/33465704",
    "http://www.ncbi.nlm.nih.gov/pubmed/33876372",
    "http://www.ncbi.nlm.nih.gov/pubmed/33025950",
    "http://www.ncbi.nlm.nih.gov/pubmed/34343033",
    "http://www.ncbi.nlm.nih.gov/pubmed/34580817",
    "http://www.ncbi.nlm.nih.gov/pubmed/32100250",
    "http://www.ncbi.nlm.nih.gov/pubmed/29233825",
    "http://www.ncbi.nlm.nih.gov/pubmed/34023541",
    "http://www.ncbi.nlm.nih.gov/pubmed/33307872",
    "http://www.ncbi.nlm.nih.gov/pubmed/33453089",
    "http://www.ncbi.nlm.nih.gov/pubmed/34552008",
    "http://www.ncbi.nlm.nih.gov/pubmed/32821296",
    "http://www.ncbi.nlm.nih.gov/pubmed/33301227",
    "http://www.ncbi.nlm.nih.gov/pubmed/32972961"
  ],
  "snippets": [
    {
      "text": "In vitro studies tested the efficacy of MRP-1 inhibitors (nilotinib, ripretinib, selumetinib, and avapritinib) in sarcoma cell lines. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34552008",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this review, we briefly outline the history of treatment for systemic mastocytosis and subsequently focus on the clinical development and potential applications of avapritinib (previously known as BLU-285), a potent and selective oral inhibitor of the tyrosine kinase most commonly mutated in this condition.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34580817",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Avapritinib is a novel, potent KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genotype. To date, only a minority of PDGFRA-mutant patients treated with avapritinib have developed secondary resistance. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32972961",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clearly, better knowledge of the molecular mechanisms underlying the resistance to imatinib as well as the development of a new class of broad-spectrum tyrosine kinase inhibitors such as avapritinib and ripretinib will provide new individualized therapeutic strategies for GIST patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33307872",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "NAVIGATOR is a two-part, single-arm, dose escalation and expansion study designed to evaluate safety and antineoplastic activity of avapritinib, a selective, potent inhibitor of KIT and PDGFRA, in patients with unresectable or metastatic GIST.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33453089",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: Targeting PDGFRA D842V-mutant GIST with avapritinib resulted in an unprecedented, durable clinical benefit, with a manageable safety profile. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33465704",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Avapritinib, a novel inhibitor of KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18-mutant unresectable or metastatic gastrointestinal stromal tumors (U/M GISTs). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33301227",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Avapritinib (AYVAKIT\u2122) is a potent and selective tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation loop mutants.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32100250",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Avapritinib is a protein kinase inhibitor designed to selectively inhibit oncogenic KIT and platelet-derived growth factor receptor alpha (PDGFRA) mutants by targeting the active conformation of the kinase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34023541",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In a phase I trial of avapritinib (formerly BLU-285), which targets D816V mutant KIT, for the treatment of advanced systemic mastocytosis, patients experienced rapid and durable disease control.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29233825",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this study, we discovered that avapritinib (BLU-285), a potent, selective, and orally bioavailable tyrosine kinase inhibitor against mutant forms of KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1 and ABCG2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31117741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Avapritinib is approved in the USA for PDGFRA exon 18 (including D842V) mutant GIST and is undergoing regulatory assessment in the USA as a 4th-line treatment for GIST.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32100250",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Avapritinib is a tyrosine kinase inhibitor (TKI) that has recently received Food and Drug Administration (FDA) approval for the treatment of metastatic or unresectable gastrointestinal stromal tumors harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33025950",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Avapritinib: A Selective Inhibitor of KIT and PDGFR\u03b1 that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31117741",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "y, United States Federal and Drug Administration (FDA) approved two new tyrosine kinase inhibitors for the treatment of heavily pretreated advanced/unresectable GIST including avapritinib (a selective inhibitor for PDGFRA exon 18 mutation including D842V mutations) and ripretinib (a broad-spectrum kinase inhibitor of c-Kit and PDGFRA). In this ar",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33876372",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In a phase I trial of avapritinib (formerly BLU-285), which targets D816V mutant KIT, for the treatment of advanced systemic mastocytosis, patients experienced rapid and durable disease control. Th",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29233825",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ibitors. We aimed to assess the safety, tolerability, and antitumour activity of avapritinib, a novel KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V, in patients with advanced gastrointestinal stromal tumours, including patients with KIT and PDGFRA D842V-mutant gastrointestinal stromal tumours (NAVIGA",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32615108",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "study, we discovered that avapritinib (BLU-285), a potent, selective, and orally bioavailable tyrosine kinase inhibitor against mutant forms of KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1 and ABCG2. Moreover, ava",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31117741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "V. Avapritinib is a novel, potent KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genoty",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32972961",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Avapritinib is a tyrosine kinase inhibitor (TKI) that has recently received Food and Drug Administration (FDA) approval for the treatment of metastatic or unresectable gastrointestinal stromal tumors harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation. Muta",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33025950",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "(GISTs). Avapritinib selectively and potently inhibits KIT- and PDGFRA-mutant",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34343033",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Avapritinib, a novel inhibitor of KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18-mutant unresectable or metastatic gastrointestinal stromal tumors ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33301227",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herein, we report a clinical case of a patient with metastatic vulvar melanoma, harboring an exon 17 c-KIT mutation, treated with avapritinib (BLU-285) - a highly potent and selective oral kinase inhibitor designed to treat imatinib-resistant gastro-intestinal stromal tumors (GIST) by targeting KIT/PDGFR\u03b1 activation loop mutants (exons 17/18).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32821296",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "utation. We tested the activity of avapritinib, a potent and highly selective inhibitor of mutated KIT and PDGFRA, in three patient-derived xenograft (PDX) GIST models carrying different KIT mutations, with differential sensitivity to standard TKI.Experimental Design: NMRI nu/nu mice (n = 93) were transplanted with human GIST xenografts with KIT exon 11+17 (UZLX-GIST9 KIT 11+17 ), exon 11 (UZLX-GIST3 KIT 11 ), or exon 9 (UZLX-GIST2B KIT9 ) mutations, resp",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30274985",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "inhibitors. We aimed to assess the safety, tolerability, and antitumour activity of avapritinib, a novel KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V, in patients with advanced gastrointestinal stromal tumours, including patients with KIT and PDGFRA D842V-mutant gastrointestinal stromal tumours (NAVIGATOR).METHODS: NAVIGATOR is a two-part, open-label, dose-escalation and dose-expansion, phase 1 study done at 17 sites across nine countries (Belgium, France, Germany, Poland, Netherlands, South Korea, Spain, ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32615108",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "KIT, PDGFRA"
}